- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02739529
Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic Cancer
April 27, 2017 updated by: Samyang Biopharmaceuticals Corporation
Dose-dense Paclitaxel (Genexol®-PM) Once a Week in Combination With Carboplatin Every 3 Weeks for Gynecologic Cancer (Adult Solid Tumor): a Phase I Trial
Dose-dense paclitaxel (Genexol®-PM) once a week in combination with carboplatin every 3 weeks for gynecologic cancer (adult solid tumor): a phase I trial.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
18
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Samyang Biopharmaceuticals
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 79 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Patients who aged 20 years or older and under 80 year old female
- Patients who were diagnosed histologically or cytologically or who were scheduled to reccur as an gynecologic cancer (epithelial ovarian cancer , fallopian tube cancer, primary peritoneal cancer, cervical cancer, uterine corpus cance, etc)
- Patients seemed appropriate for Paclitaxel and Carboplatin combination therapy for the treatment
- Patients whose ECOG performance score are 0-2
Patients who have adequate blood, kidney and liver function on screening within 14 days before the administration of the test drugs
- Hb ≥ 10g/dl: Patients with less than 10g/dl of hemoglobin level were not allowed to use the test drugs unless they were recovered to 10g/dl or more.
- ANC ≥ 1500/mm3
- Platelet Count ≥ 100,000/mm3
- Serum AST and ALT ≤ 2.5 X ULN
- Serum ALP ≤ 2.5 X ULN
- Serum creatinine ≤ 2.5 X ULN
- Patients who participated voluntarily and who provided written informed consent before participating in the study
Exclusion Criteria:
- Patients with the history of carcinoma in the past 5 years other than gynecologic cancer
- Patients who received radiotherapy at abdominal cavity or pelvis
- Patients who were receiving immunotherapy or hormone therapy
- Patients who received a major surgery other than debulking surgery within 2 weeks before the screening
- Patients with a past or present medical history of metastasis in central nervous system (CNS)
- Patients with NCI CTCAE V4.0 Grade 1 or more sensory or motor neuropathy
Patients with severe comorbidities as follows
- medical or mental condition impossible to understand the clinical trial and provide a written informed consent, based on the investigators' decision
- severe cardiovascular disease (such as ischemic heart disease requiring medical therapy, myocardial infarction within the last 6 months, and grade 2~4 congestive heart failure defined by New York Heart Association criteria)
- uncontrolled active infectious disease
- hypersensitivity to the test drugs or the vehicle
- Patients who participated in another study within 4 weeks before the screening
- Pregnant, lactating women or Patients who do not use contraceptive methods that can be medically accepted to the possibility of pregnancy in female volunteers
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cohort 1
Genexol-PM 100mg/m2 IV infusion D1,D8,D15 Carboplatin 5 AUC IV infusion D1
|
Cremophor EL-free polymeric micelle of paclitaxel
|
EXPERIMENTAL: Cohort 2
Genexol-PM 120mg/m2 IV infusion D1,D8,D15 Carboplatin 5 AUC IV infusion D1
|
Cremophor EL-free polymeric micelle of paclitaxel
|
EXPERIMENTAL: Cohort 3
Genexol-PM 120mg/m2 IV infusion D1,D8,D15 Carboplatin 6 AUC IV infusion D1
|
Cremophor EL-free polymeric micelle of paclitaxel
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The recommended dose for the phase II study
Time Frame: 2 years
|
Determined as the recommended dose for a phase 2 study based on the adverse events and toxicities at each dose groups
|
2 years
|
The maximum tolerated dose (MTD)
Time Frame: 2 years
|
MTD was determined as the dose where more than 2 out of 6 subjects experienced DLT
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The dose limiting toxicity (DLT)
Time Frame: 2 years
|
Dose limiting toxicity (DLT) was defined as one of the following cases.
NCI CTCAE V3.0 Grade 3 or more hypersensitivity despite premedication, Non-Hematological Toxicity other than nausea and vomiting, Hematological toxicity.
|
2 years
|
Toxicities
Time Frame: 2 years
|
Clinical/laboratory toxicities were monitored after the treatment, in order to evaluate safety and tolerance of the test drugs, and adverse events, which were maintained until visit on discontinuation date, were followed until recovered or stabilized
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yong Man Kim, Asan Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2016
Primary Completion (ANTICIPATED)
March 1, 2018
Study Completion (ANTICIPATED)
March 1, 2018
Study Registration Dates
First Submitted
March 21, 2016
First Submitted That Met QC Criteria
April 14, 2016
First Posted (ESTIMATE)
April 15, 2016
Study Record Updates
Last Update Posted (ACTUAL)
May 1, 2017
Last Update Submitted That Met QC Criteria
April 27, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- GPMOC101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gynecologic Cancer
-
University of LouisvilleJames Graham Brown Cancer CenterCompleted
-
Shandong UniversityCompletedGynecologic Cancer | Gynecologic DiseaseChina
-
Washington University School of MedicineWashington University Department of Psychological and Brain SciencesTerminatedStage III Gynecologic Cancer | Stage IV Gynecologic CancerUnited States
-
Azienda Socio Sanitaria Territoriale degli Spedali...CompletedGynecologic Cancer | Surgery | Anesthesia | Hysterectomy | Gynecologic DiseaseItaly
-
Peking Union Medical College HospitalNot yet recruitingGynecologic Cancer
-
IRCCS Policlinico S. MatteoNot yet recruiting
-
Fudan UniversityGuangzhou Burning Rock Dx Co., Ltd.Recruiting
-
Fox Chase Cancer CenterCompleted
-
University Hospital, GenevaCompletedGynecologic CancerSwitzerland
-
Fudan UniversityGuangzhou Burning Rock Bioengineering Ltd.Active, not recruiting
Clinical Trials on Genexol-PM
-
Samyang Biopharmaceuticals CorporationCompleted
-
Samyang Biopharmaceuticals CorporationCompletedBreast CancerKorea, Republic of
-
Samyang Biopharmaceuticals CorporationCompleted
-
Asan Medical CenterSamsung Medical Center; Kangdong Sacred Heart HospitalCompletedBladder Cancer | Ureter CancerKorea, Republic of
-
Samyang Biopharmaceuticals CorporationCompleted
-
Samyang Biopharmaceuticals CorporationCompletedNon Small Cell Lung CancerKorea, Republic of
-
National Cancer Center, KoreaWithdrawn
-
Gachon University Gil Medical CenterTerminatedCarcinoma, HepatocellularKorea, Republic of
-
Gachon University Gil Medical CenterUnknownMetastatic Breast CancerKorea, Republic of
-
Korean Breast Cancer Study GroupUnknownRecurrent Breast CancerKorea, Republic of